Advances in the Treatment of Autoimmune Nodopathy

The two papes reviewed here discuss advances in the treatment of of autoimmune nodopathy (AN), a rare neurological condition formerly grouped with chronic inflammatory demyelinating polyradiculoneuropathy. Unlike traditional cases, AN involves pathogenic IgG4 autoantibodies that target specific proteins at the nodes of Ranvier, making patients largely resistant to standard treatments like intravenous immunoglobulin. Research involving 118 patients reveals a high clinical response rate of 92% for those receiving B-cell depleting therapies such as rituximab and ofatumumab. While the therapy appears highly effective for subtypes like anti-NF155 and anti-CNTN1, the sources report a safety profile that includes risks of serious infection and rare fatalities. Ultimately, the authors conclude that while results are promising, the lack of randomized controlled trials means these findings are not yet practice-changing. Further prospective studies are required to establish standardized dosing and confirm the long-term safety of this precision medicine approach.